-
Posted by
Two Blokes Jun 18 -
Filed in
Stock
-
5 views
Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network NEW YORK , June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics' EsoGuard\u00ae Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, primary care, and concierge medicine programs.
